<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490994</url>
  </required_header>
  <id_info>
    <org_study_id>4-2017-0776</org_study_id>
    <nct_id>NCT03490994</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)</brief_title>
  <official_title>Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin K antagonists (VKAs) are used to reduce the risk of stroke (cerebral vascular
      dysfunction) in AF patients. However, VKAs interact with drugs/food and the drug level is
      influenced by worsening of renal function, liver congestion or hemodynamic alterations in
      acute decompensated heart failure (ADHF). New oral anticoagulants (rivaroxaban, apixaban,
      dabigatran) are alternatives to VKA, such as warfarin. In post hoc analysis of ROCKET AF
      trial, 63.7% patients had HF and treatment-related outcomes were similar in patients with and
      without HF (Circulation HF. 2013; 6:740-7). So rivaroxaban 20 mg daily (or 15 mg daily in
      patients with creatinine clearance 30-49 mL/min) was safe in nonvalvular AF patients with HF.
      However, the clinical effect and safety of rivaroxaban were largely unknown in acute
      decompensated heart failure (ADHF) patients with atrial fibrillation (AF).

      ROAD HF-AF is the exploratory study to assess the change of surrogate markers (hsTn, d-dimer)
      when treated with rivaroxaban vs. warfarin and to strengthen the basis for future
      biomarker-based therapy in ADHF patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>warfarin vs. rivaroxaban</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of high sensitive troponin</measure>
    <time_frame>Baseline to 72 hours</time_frame>
    <description>The maximum hsTn value change from baseline to during hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) the change of hish sensitive troponin</measure>
    <time_frame>1) On admission, hospital day #2, hospital day #4, hospital day #7 or discharge, 1 month/6month after discharge</time_frame>
    <description>1) The change from baseline in hsTn on Day2, day4, day7 (or discharge), and follow-up visits at 1 month, 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2) the change of D-dimer</measure>
    <time_frame>2) On admission, hospital day #2, hospital day #4, hospital day #7 or discharge, 1 month/6month after discharge</time_frame>
    <description>2) D-dimer change from baseline during hospitalization (day2, day4, day7 or discharge) &amp; follow-up visits at 1, 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) the change of NT-proBNP</measure>
    <time_frame>3) On admission, hospital day #7 or discharge, 1 month/6month after discharge</time_frame>
    <description>3) TAT complex, PAI-1, hsCRP, NT-proBNP, sST2, galectin-3, cystatin C, NGAL, NAG change from baseline to day7 or discharge &amp; 1,6 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4) bleeding event</measure>
    <time_frame>4) On admission, hospital day #2, hospital day #4, hospital day #7 or discharge, 1 month/3month/6month after discharge</time_frame>
    <description>4) Incidence proportion and rate of major/minor bleeding during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5) hospital stay</measure>
    <time_frame>5) The duration of hospital stay, average 7 days</time_frame>
    <description>5) Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6) all-cause mortality</measure>
    <time_frame>6) 6 months after hospitalization</time_frame>
    <description>6) Incidence proportion of in-hospital all-cause death cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7) all-cause hospitalization &amp; mortality</measure>
    <time_frame>7) 6 months after hospitalization</time_frame>
    <description>7) Time to the first composite event of all-cause mortality or cardiovascular re-hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin + enoxaparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin + LMWH</intervention_name>
    <description>dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Hospitalized patients with a primary diagnosis of ADHF with AF One of
        the following criteria and LVEF â‰¤ 40% (at least 1 year before admission or admission)

          1. dyspnea at rest

          2. tachypnea; a respiratory rate &gt; 20/min

          3. rales

          4. pulmonary edema on chest X-ray

        Exclusion Criteria:

          1. History of increased bleeding risk (like ROCKET AF exclusion criteria)

          2. Contraindication to anti-coagulation therapy

          3. ACS diagnosis

          4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiac
             invasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)

          5. Currently on dual anti-platelet therapy (aspirin + ADP receptor antagonist) or single
             antiplatelet therapy with a novel AP (e.g. Ticagrelor, Prasugrel)

          6. Cardiogenic shock (systolic blood pressure, SBP, &lt; 80 mmHg)

          7. Patients with CrCl &lt; 30 ml/min using creatinine-based CKD-EPI equations

          8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis

          9. Uncontrolled hypertension (SBP &gt; 180 mmHg)

         10. Allergy, adverse drug reaction, hypersensitivity to rivaroxaban or warfarin

         11. Life expectancy &lt; 6 months (e.g. metastatic malignancy)

         12. Pregnancy, or women of childbearing age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seok-Min Kang, MD</last_name>
    <phone>82-2-2228-8450</phone>
    <email>smkang@yuhs.ac</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>April 1, 2018</last_update_submitted>
  <last_update_submitted_qc>April 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

